慢病毒基因治疗β-血红蛋白病的长期结局:HGB-205试验
HGB-205是一项1/2期开放标签单臂非随机干预研究,在单中心纳入4例输血依赖型β-地中海贫血(TDT)和3例镰状细胞病(SCD)患者,年龄13-21岁,经白消安清髓后输注慢病毒载体BB305转导的自体CD34+细胞。中位随访4.5年,未观察到与药品相关的不良事件;2例SCD患者持续临床缓解,1例输血频率降低,4例TDT患者均脱离输血。
要点
- HGB-205纳入4例TDT和3例SCD患者,中位随访4.5年,未观察到与药品相关的不良事件。
- 3例SCD中2例持续临床缓解和生物学标志改善,第3例输血频率降低。
- 4例TDT患者均脱离输血,红系造血异常和铁过载改善。
核心结论
- 慢病毒载体BB305基因治疗在HGB-205中使4例TDT患者全部脱离输血,3例SCD中2例持续临床缓解、1例输血频率降低,未观察到与药品相关的不良事件。
研究设计与样本
- HGB-205(NCT02151526)是一项1/2期、开放标签、单臂、非随机干预研究,在单中心进行,为期2年,随后分别进入TDT和SCD的长期随访研究LTF-303(NCT02633943)和LTF-307(NCT04628585)观察。
- 纳入标准与异基因移植相似,但限于缺乏基因型相同、组织相容供者的患者。
- 共治疗4例TDT和3例SCD患者,年龄13-21岁,经白消安清髓后输注慢病毒载体BB305转导的自体CD34+细胞,治疗距报告时4.6-7.9年,中位随访4.5年。
主要发现
- 未观察到与药品相关的不良事件。
- 3例SCD患者中2例持续临床缓解和疾病生物学标志改善,第3例输血频率降低。
- 4例TDT患者全部脱离输血,红系造血异常和铁过载改善。
关键数值与推荐
- 关键主要终点包括死亡率、植入、复制 competent 慢病毒和克隆优势。
- 慢病毒载体BB305编码在红系谱系表达的抗镰变βA-T87Q-珠蛋白。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are the most prevalent monogenic disorders worldwide. Trial HGB-205 ( NCT02151526 ) aimed at evaluating gene therapy by autologous CD34+ cells transduced ex vivo with lentiviral vector BB305 that encodes the anti-sickling βA-T87Q-globin expressed in the erythroid lineage. HGB-205 is a phase 1/2, open-label, single-arm, non-randomized interventional study of 2-year duration at a single center, followed by observation in long-term follow-up studies LTF-303 ( NCT02633943 ) and LTF-307 ( NCT04628585 ) for TDT and SCD, respectively. Inclusion and exclusion criteria were similar to those for allogeneic transplantation but restricted to patients lacking geno-identical, histocompatible donors. Four patients with TDT and three patients with SCD, ages 13-21 years, were treated after busulfan myeloablation 4.6-7.9 years ago, with a median follow-up of 4.5 years. Key primary endpoints included mortality, engraftment, replication-competent lentivirus and clonal dominance. No adverse events related to the drug product were observed. Clinical remission and remediation of biological hallmarks of the disease have been sustained in two of the three patients with SCD, and frequency of transfusions was reduced in the third. The patients with TDT are all transfusion free with improvement of dyserythropoiesis and iron overload.
引用
- Magrin E, Semeraro M, Hebert N, et al. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial. Nat Med. 2022. PMID: 35075288. doi:10.1038/s41591-021-01650-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。